Anavex Life Sciences Corp. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Anavex Life Sciences Corp. is holding its 2024 Annual Meeting of Stockholders on June 18, 2024, with proxy materials primarily distributed online.</b>

AI Summary

ANAVEX LIFE SCIENCES CORP. (AVXL) filed a Proxy Statement (DEF 14A) with the SEC on May 6, 2024. Anavex Life Sciences Corp. will hold its 2024 Annual Meeting of Stockholders on June 18, 2024, at 10:00 a.m. EDT. The meeting will take place at the offices of K&L Gates LLP, 599 Lexington Avenue, New York, NY 10022. Most stockholders will receive a Notice of Internet Availability of Proxy Materials instead of paper copies. This notice provides instructions for accessing proxy materials and voting online. Stockholders can request a paper copy of proxy materials if desired.

Why It Matters

For investors and stakeholders tracking ANAVEX LIFE SCIENCES CORP., this filing contains several important signals. The shift to online distribution of proxy materials aims to reduce environmental impact and lower printing and distribution costs. Encouraging early voting ensures stockholder representation at the meeting, regardless of attendance.

Risk Assessment

Risk Level: low — ANAVEX LIFE SCIENCES CORP. shows low risk based on this filing. The filing is a routine DEF 14A proxy statement, indicating standard corporate governance procedures rather than significant operational or financial changes.

Analyst Insight

Stockholders should review the proxy statement for details on voting matters and consider voting early to ensure their shares are represented.

Key Numbers

• 2024 — Annual Meeting Year (2024 Annual Meeting of Stockholders)
• June 18 — Meeting Date (Tuesday, June 18, 2024)
• 10:00 a.m. EDT — Meeting Time (10:00 a.m. Eastern Daylight Time)

Key Players & Entities

• ANAVEX LIFE SCIENCES CORP. (company) — Registrant name
• K&L Gates LLP (company) — Location of the annual meeting
• June 18, 2024 (date) — Date of the annual meeting
• 10:00 a.m. Eastern Daylight Time (time) — Time of the annual meeting
• 630 Fifth Avenue, 20th Floor, New York, NY 10111 (address) — Company's business and mailing address

FAQ

Industry Context

Anavex Life Sciences Corp. is a biopharmaceutical company focused on developing treatments for neurological disorders. This filing pertains to its annual shareholder meeting and proxy materials.

Regulatory Implications

This filing is a Definitive Proxy Statement (DEF 14A) filed under the Securities Exchange Act of 1934, outlining information for stockholders regarding the annual meeting and voting procedures.

What Investors Should Do

1. Review the proxy statement for details on proposals and voting matters.
2. Vote your shares online, by phone, or by mail as instructed.
3. Consider attending the annual meeting on June 18, 2024, if possible.

Key Dates

• 2024-06-18: 2024 Annual Meeting of Stockholders — Key date for stockholder voting and participation.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual proxy statement and does not represent a change from previous filings of this type.

Key Financial Figures

• $0.001 — Sciences Corp. common stock, par value $0.001 per share (&ldquo; Common Stock &rdquo;
• $10 billion — by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas&rsquo; legal practice cover

Filing Documents

• e5638_def14a.htm (DEF 14A) — 558KB
• image_001.jpg (GRAPHIC) — 4KB
• image_001.gif (GRAPHIC) — 5KB
• image_002.gif (GRAPHIC) — 5KB
• image_003.gif (GRAPHIC) — 5KB
• img_005.jpg (GRAPHIC) — 424KB
• img_006.jpg (GRAPHIC) — 477KB
• 0001731122-24-000730.txt (&nbsp;) — 1827KB

Executive Compensation Overview

Executive Compensation Overview 21 Our Executive Compensation Program and Philosophy 21 Compensation Risk Oversight 22 Compensation Consultants 22 Elements of Executive Compensation 22 Insider Trading Policy 23 Clawback Policy 24 Stock Ownership Guidelines 24 Results of 2021 Say-on-Pay Advisory Vote 24 Summary Compensation 25 Employment Agreements 25 Equity Compensation 25 Grants of Plan-Based Awards 25 Outstanding Equity Awards at Fiscal Year-End 26 Option Exercises and Stock Vested 28 Nonqualified Defined Contribution and Other Nonqualified Deferred Compensation Plans 28 CEO Pay Ratio Disclosure 28 Pay Versus Performance 29 Compensation of Directors 32 Commitment to Corporate Responsibility 34

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 35 Delinquent Section 16(A) Reports 37 Future Stockholder Proposals 37 No Dissenters&rsquo; Rights 37 Code of Ethics and Conduct 37 Transactions with Related Persons 37 Other Matters 38 2024 Meeting Proxy Materials Results 38 Delivery of Documents to Stockholders Sharing an Address 38 2 PROXY STATEMENT FOR THE 2024 MEETING OF STOCKHOLDERS ______________________ Anavex Life Sciences Corp. (&ldquo; we ,&rdquo; &ldquo; us ,&rdquo; &ldquo; our ,&rdquo; &ldquo; Anavex ,&rdquo; or the &ldquo; Company &rdquo;) is providing these proxy materials in connection with the 2024 Annual Meeting of Stockholders of Anavex Life Sciences Corp. (the &ldquo; 2024 Meeting &rdquo;). This proxy statement contains important information for you to consider when deciding how to vote on the matters brought before the 2024 Meeting. QUESTIONS AND ANSWERS ABOUT THE 2024 MEETING Q: When and where is the 2024 Meeting? A: The 2024 Meeting is being held Tuesday, June 18, 2024, 10:00 a.m., Eastern Daylight Time (EDT). The 2024 Meeting will be held at the offices of K&L Gates LLP, 599 Lexington Avenue, New York, NY 10022. Q: Who is entitled to vote at the 2024 Meeting? A: Holders of Anavex Life Sciences Corp. common stock, par value $0.001 per share (&ldquo; Common Stock &rdquo;), at the close of business on April 26, 2024, the record date for the 2024 Meeting (the &ldquo; Record Date &rdquo;) established by our board of directors (the &ldquo; Board &rdquo;), are entitled to receive notice of the 2024 Meeting (the &ldquo; Meeting Notice &rdquo;), and to vote their shares at the 2024 Meeting and any related adjournments or postponements. The Meeting Notice, proxy statement and form of proxy are first expected to be made available to stockholders on or about May 6, 2024. As of the close of business on the Record Date, there were 84,641,537 shares of our Common Stock outstanding and entitled to vot

View Full Filing

View this DEF 14A filing on SEC EDGAR